{"id":743785,"date":"2013-07-16T11:01:00","date_gmt":"2013-07-16T11:01:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/"},"modified":"2023-03-22T00:04:36","modified_gmt":"2023-03-22T04:04:36","slug":"merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/","title":{"rendered":"Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      confirmed today that the U.S. Food and Drug Administration (FDA) has<br \/>\n      cancelled Thursday\u2019s discussion of sugammadex at the Anesthetic and<br \/>\n      Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium<br \/>\n      injection is Merck\u2019s investigational medicine for the reversal of<br \/>\n      neuromuscular blockade (NMB) induced by rocuronium or vecuronium.\n    <\/p>\n<p>\n      The FDA advised Merck that the agency needs additional time to assess<br \/>\n      the results of the FDA\u2019s recently completed inspection of a clinical<br \/>\n      trial site. The site was one of four sites that conducted the<br \/>\n      hypersensitivity study previously requested by the agency. Merck is<br \/>\n      engaged in discussions with the FDA to identify the steps necessary to<br \/>\n      enable the agency to complete its review.\n    <\/p>\n<p>\n      \u201cMerck believes that sugammadex is an important treatment option for an<br \/>\n      unmet medical need in anesthesia, and we will work with the FDA on the<br \/>\n      next steps to bring this innovation forward to patients in the United<br \/>\n      States,\u201d said David Michelson, M.D., head of global clinical development<br \/>\n      for neuroscience, Merck Research Laboratories.\n    <\/p>\n<p>\n      Sugammadex is marketed in 40 countries other than the U.S., and more<br \/>\n      than five million vials of sugammadex have been sold as of March 2013.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50671202&#038;newsitemid=20130716006147&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=cef76fb30345985d3142918ce8c227a4\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50671202&#038;newsitemid=20130716006147&#038;lan=en-US&#038;anchor=Twitter&#038;index=2&#038;md5=541b89bd73fba345078870b91189b7d1\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50671202&#038;newsitemid=20130716006147&#038;lan=en-US&#038;anchor=Facebook&#038;index=3&#038;md5=4dec9ce2fd639103ce7bccaa145fd022\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50671202&#038;newsitemid=20130716006147&#038;lan=en-US&#038;anchor=YouTube&#038;index=4&#038;md5=c993f93c38d5b082926a59fddad34455\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50671202&#038;newsitemid=20130716006147&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=5&#038;md5=eb8369928d501a6530899ff73fee5f96\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130716006147r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 908-423-5042<br \/>Sarra Herzog,        908-423-6154<br \/>or<br \/>Investors:<br \/>Carol Ferguson, 908-423-4465<br \/>Justin        Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed today that the U.S. Food and Drug Administration (FDA) has cancelled Thursday\u2019s discussion of sugammadex at the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium injection is Merck\u2019s investigational medicine for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. The FDA advised Merck that the agency needs additional time to assess the results of the FDA\u2019s recently completed inspection of a clinical trial site. The site was one of four sites that conducted the hypersensitivity study previously requested by the agency. Merck is engaged in discussions with the FDA to identify the steps necessary to enable the agency to complete its review. \u201cMerck believes that sugammadex is an important treatment option for an unmet medical need in anesthesia, and we will work with the FDA on the next steps to bring this innovation forward to patients in the<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-743785","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed today that the U.S. Food and Drug Administration (FDA) has cancelled Thursday\u2019s discussion of sugammadex at the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium injection is Merck\u2019s investigational medicine for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. The FDA advised Merck that the agency needs additional time to assess the results of the FDA\u2019s recently completed inspection of a clinical trial site. The site was one of four sites that conducted the hypersensitivity study previously requested by the agency. Merck is engaged in discussions with the FDA to identify the steps necessary to enable the agency to complete its review. \u201cMerck believes that sugammadex is an important treatment option for an unmet medical need in anesthesia, and we will work with the FDA on the next steps to bring this innovation forward to patients in the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:36+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130716006147r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\\\/\",\"name\":\"Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130716006147r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-07-16T11:01:00+00:00\",\"dateModified\":\"2023-03-22T04:04:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130716006147r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130716006147r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/","og_locale":"en_US","og_type":"article","og_title":"Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed today that the U.S. Food and Drug Administration (FDA) has cancelled Thursday\u2019s discussion of sugammadex at the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium injection is Merck\u2019s investigational medicine for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. The FDA advised Merck that the agency needs additional time to assess the results of the FDA\u2019s recently completed inspection of a clinical trial site. The site was one of four sites that conducted the hypersensitivity study previously requested by the agency. Merck is engaged in discussions with the FDA to identify the steps necessary to enable the agency to complete its review. \u201cMerck believes that sugammadex is an important treatment option for an unmet medical need in anesthesia, and we will work with the FDA on the next steps to bring this innovation forward to patients in the","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:36+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130716006147r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/","name":"Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130716006147r1&sid=sfsite1&distro=nx","datePublished":"2013-07-16T11:01:00+00:00","dateModified":"2023-03-22T04:04:36+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130716006147r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130716006147r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-about-sugammadex-sodium-injection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"452f62a3-c37d-43e0-9c92-3ea37ab0f098","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743785\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743785"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}